AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7955677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile cast (30 patients)
Number of subjects: 60
Study 7955677 — intervention group
Group type: COMPARATOR
Intervention: Rigid below-knee cast (30 patients)
Number of subjects: 60
Study 3315677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806
Study 3315677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study 31915153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg (n = 26)
Number of subjects: 38
Study 31915153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 38
Study 31915153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg (n = 26) under glucose clamp conditions
Number of subjects: 38
Study 31915153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12) under glucose clamp conditions
Number of subjects: 38
Study 31915153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg (n = 26) under pancreatic clamp conditions
Number of subjects: 38
Study 31915153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12) under pancreatic clamp conditions
Number of subjects: 38
Study 29631747 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Number of subjects: 591
Study 29631747 — intervention group
Group type: COMPARATOR
Intervention: Otic drops
Number of subjects: 591
Study 28601965 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 59
Study 28601965 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (25 mg)
Number of subjects: 59
Study 28601965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 28601965 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy
Number of subjects: 59
Study 28601965 — intervention group
Group type: EXPERIMENTAL
Intervention: Centroparietal positivities (Pe and feedback-locked P300)
Number of subjects: 59
Study 26328785 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 79
Study 26328785 — intervention group
Group type: COMPARATOR
Intervention: Traditional Dental Health Education (DHE)
Number of subjects: 79
Study 23157937 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of dialysis (GFR 10-14 mL/min/1.73 m²)
Number of subjects: 182
Study 23157937 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of dialysis (GFR 5-7 mL/min/1.73 m²)
Number of subjects: 182
Study 23157937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late initiation of dialysis
Number of subjects: 182
Study 21600709 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Intervention (OTI)
Number of subjects: 400
Study 21600709 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment Model (CTM)
Number of subjects: 400
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for galenic DAVF using posterior interhemispheric approach
Number of subjects: 31
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for straight sinus DAVF using supracerebellar-infratentorial approach
Number of subjects: 31
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for torcular DAVF using torcular craniotomy
Number of subjects: 31
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for tentorial sinus DAVF using supratentorial-infraoccipital approach
Number of subjects: 31
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for superior petrosal sinus DAVF using extended retrosigmoid approach
Number of subjects: 31
Study 18424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment for incisural DAVF using pterional or subtemporal approach
Number of subjects: 31
Study 16585302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens)
Number of subjects: 4114
Study 16585302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 4114
Study 16585302 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine (control)
Number of subjects: 4114
Study 12827403 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI
Number of subjects: 134
Study 12827403 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 134
Study 11523062 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril suspension (10 mg)
Number of subjects: 16
Study 11523062 — intervention group
Group type: COMPARATOR
Intervention: VASOTEC tablets (10 mg)
Number of subjects: 16
Study 9190554 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/kg/day of cephradine divided in four doses
Number of subjects: 50
Study 9190554 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg/day in four doses of clindamycin
Number of subjects: 50
Study 31429705 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R variant rs12970134 (A/G)
Number of subjects: 189
Study 31429705 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R variant rs17782313 (C/T)
Number of subjects: 189
Study 31429705 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese PCOS group (BMI < 30 kg/m2) with genotypes AG/GG for rs12970134 and CT/TT for rs17782313
Number of subjects: 189
Study 31429705 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PCOS women)
Number of subjects: 189
Study 28107288 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 1.0 g/L 2'fucosyllactose (2'FL) and 0.5 g/L lacto‐N‐neotetraose (LNnT)
Number of subjects: 175
Study 28107288 — intervention group
Group type: COMPARATOR
Intervention: Intact‐protein, cow's milk‐based infant formula (control)
Number of subjects: 175
Study 26571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1000 mg once daily (QD)
Number of subjects: 28
Study 26571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg once daily (QD)
Number of subjects: 28
Study 26571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 500 mg twice daily (BID)
Number of subjects: 28
Study 26571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (various doses)
Number of subjects: 28
Study 23164462 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-I disorder with a positive CBCL-severe dysregulation profile (N=80)
Number of subjects: 140
Study 23164462 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-I disorder without a positive CBCL-severe dysregulation profile (N=60)
Number of subjects: 140
Study 23164462 — intervention group
Group type: COMPARATOR
Intervention: Controls (N=129)
Number of subjects: 140
Study 21792527 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (3 g)
Number of subjects: 0
Study 21792527 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (3.5 mg)
Number of subjects: 0
Study 18625084 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials of psychological therapies
Number of subjects: 4673
Study 18625084 — intervention group
Group type: COMPARATOR
Intervention: Practice-based studies of psychological therapies
Number of subjects: 4673
Study 15897790 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 45
Study 15897790 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 45
Study 12884461 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid pre-treatment with Blu-U light
Number of subjects: 22
Study 12884461 — intervention group
Group type: COMPARATOR
Intervention: Blu-U light alone
Number of subjects: 22
Study 10589636 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 65
Study 10589636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 microg/mL
Number of subjects: 65
Study 10589636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of levobupivacaine 0.125% and fentanyl 4 microg/mL
Number of subjects: 65
Study 8755850 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 allele and homozygotus genotype P1P1 for the INSR gene
Number of subjects: 192
Study 8755850 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotus genotype Pu1Pu2
Number of subjects: 192
Study 8755850 — intervention group
Group type: COMPARATOR
Intervention: PvuII RFLP in the apoB gene locus
Number of subjects: 192
Study 1745997 — intervention group
Group type: EXPERIMENTAL
Intervention: Innohep 1,250 AFXa u
Number of subjects: 8
Study 1745997 — intervention group
Group type: EXPERIMENTAL
Intervention: Innohep 2,500 AFXa u
Number of subjects: 8
Study 1745997 — intervention group
Group type: EXPERIMENTAL
Intervention: Innohep 5,000 AFXa u
Number of subjects: 8
Study 1745997 — intervention group
Group type: COMPARATOR
Intervention: UFH 5,000 iu + 1,500 iu/h
Number of subjects: 8
Study 7036764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 85
Study 7036764 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine combined with chloroquine (10 mg/kg)
Number of subjects: 85
Study 31994596 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM)
Number of subjects: 15
Study 31994596 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft technique (CTG)
Number of subjects: 15
Study 30661488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents (OHAs)
Number of subjects: 172
Study 28446500 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary concentrations of homovanillyl alcohol (HVAL)
Number of subjects: 1851
Study 28446500 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of HVAL compared to lowest
Number of subjects: 1851
Study 26694596 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose omega-3 fish oil (4.5 g eicosapentaenoic acid and docosahexaenoic acid daily)
Number of subjects: 202
Study 26694596 — intervention group
Group type: COMPARATOR
Intervention: Low dose omega-3 fish oil (0.45 g/day)
Number of subjects: 202
Study 25212703 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab HYP (50, 150, or 300 mg subcutaneous; 100 or 200 mg biweekly subcutaneous with a 200 mg loading dose; 200 or 400 mg intravenous)
Number of subjects: 70
Study 21505898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg orally qid on days 2-5 plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Number of subjects: 162
Study 21505898 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Number of subjects: 162
Study 21505898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide group
Number of subjects: 162
Study 21505898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 19204202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uracil-tegafur (UFT) for 2 years
Number of subjects: 733
Study 19204202 — intervention group
Group type: COMPARATOR
Intervention: Classical cyclophosphamide, methotrexate, and fluorouracil (CMF) for six cycles
Number of subjects: 733
Study 17713157 — intervention group
Group type: COMPARATOR
Intervention: CPG 10101 (ACTILON) 0.25 to 20 mg administered subcutaneously, twice, 14 days apart; 4 mg administered twice weekly for four weeks
Number of subjects: 48
Study 17713157 — intervention group
Group type: COMPARATOR
Intervention: CPG 10101 (ACTILON)
Number of subjects: 48
Study 15533089 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping in problem-based learning scenario discussions (experimental group)
Number of subjects: 0
Study 15533089 — intervention group
Group type: COMPARATOR
Intervention: Traditional course (control group)
Number of subjects: 0
Study 11555846 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP2 Thr54 allele
Number of subjects: 60
Study 11555846 — intervention group
Group type: COMPARATOR
Intervention: Ala54 homozygotes
Number of subjects: 60
Study 11555846 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme genotype
Number of subjects: 60
Study 11555846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln27Glu beta(2)-adrenergic receptor variant
Number of subjects: 60
Study 11555846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro12Ala peroxisome proliferator-activated receptor gamma variant
Number of subjects: 60
Study 9758732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of methylprednisolone intravenously upon induction of anesthesia
Number of subjects: 28
Study 9758732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 28
Study 7887827 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated membrane oxygenator (Group H)
Number of subjects: 14
Study 7887827 — intervention group
Group type: COMPARATOR
Intervention: Uncoated membrane oxygenator (Group C)
Number of subjects: 14
Study 3422246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX mouthrinse
Number of subjects: 32
Study 3422246 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% H2O2 mouthrinse
Number of subjects: 32
Study 3422246 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 32
Study 31427878 — intervention group
Group type: EXPERIMENTAL
Intervention: TopAnalg
Number of subjects: 14
Study 31427878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28603098 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg per day)
Number of subjects: 55
Study 28603098 — intervention group
Group type: COMPARATOR
Intervention: Silymarin (5 mg/kg per day)
Number of subjects: 55
Study 25451415 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified protocol for multiple emotional disorders (transdiagnostics) - 12 intervention sessions
Number of subjects: 48
Study 25451415 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 48
Study 23812513 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream with breastfeeding (EB group)
Number of subjects: 90
Study 23812513 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream with oral distilled water (EW group)
Number of subjects: 90
Study 23812513 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream with oral distilled water (PCW group)
Number of subjects: 90
Study 21415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-belonging intervention
Number of subjects: 92
Study 19783539 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 75
Study 19783539 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS
Number of subjects: 75
Study 19783539 — intervention group
Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 75
Study 17121873 — intervention group
Group type: EXPERIMENTAL
Intervention: 105AD7 vaccination
Number of subjects: 67
Study 17121873 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 67
Study 12602646 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 0
Study 10933370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 10933370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10933370 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 10933370 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 9101850 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-j-pouch (CPA)
Number of subjects: 63
Study 9101850 — intervention group
Group type: COMPARATOR
Intervention: Colo-anal anastomosis (CAA)
Number of subjects: 63
Study 1836676 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education intervention
Number of subjects: 29
Study 6441201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-CO2 with diazepam premedication
Number of subjects: 0
Study 6441201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-HCI with diazepam premedication
Number of subjects: 0
Study 6441201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-CO2 without diazepam premedication
Number of subjects: 0
Study 6441201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-HCI without diazepam premedication
Number of subjects: 0
Study 30897464 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Behavior Therapy (P-CBT)
Number of subjects: 49
Study 30897464 — intervention group
Group type: COMPARATOR
Intervention: Traditional Cognitive Behavior Therapy (T-CBT)
Number of subjects: 49
Study 30897464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (P-CBT and T-CBT)
Number of subjects: 49
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg (201 eyes)
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 1.25 mg (185 eyes)
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg (192 eyes)
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: All anti-VEGF treatments
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior panretinal photocoagulation (PRP)
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: African American participants
Number of subjects: 660
Study 30676635 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with central subretinal fluid
Number of subjects: 660
Study 28794001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stents (RESs)
Number of subjects: 1919
Study 28794001 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 1919
Study 25840552 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminders
Number of subjects: 0
Study 23467003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors)
Number of subjects: 0
Study 23467003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 20620118 — intervention group
Group type: EXPERIMENTAL
Intervention: Short immobilisation (1.5 hours)
Number of subjects: 104
Study 20620118 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 hours immobilisation)
Number of subjects: 104
Study 19124705 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported consistent condom use (100% condom use)
Number of subjects: 715
Study 19124705 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported consistent condom use with a history of sexually transmitted diseases
Number of subjects: 715
Study 17079637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 50 microg x kg(-1) iv (max 5 mg)
Number of subjects: 212
Study 17079637 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 212
Study 15646194 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + ET
Number of subjects: 35
Study 15646194 — intervention group
Group type: EXPERIMENTAL
Intervention: UB + ET
Number of subjects: 35
Study 15646194 — intervention group
Group type: EXPERIMENTAL
Intervention: RT only
Number of subjects: 35
Study 15646194 — intervention group
Group type: EXPERIMENTAL
Intervention: ET only
Number of subjects: 35
Study 11149991 — intervention group
Group type: EXPERIMENTAL
Intervention: Active heat-steam treatment of homes
Number of subjects: 30
Study 11149991 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (group 3)
Number of subjects: 30
Study 10193217 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 50
Study 10193217 — intervention group
Group type: COMPARATOR
Intervention: 0.75% racemic bupivacaine
Number of subjects: 50
Study 7826909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (125 mg/m2 over 24 hours)
Number of subjects: 33
Study 7826909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2 over 3 hours)
Number of subjects: 33
Study 3042041 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and placebo (group I)
Number of subjects: 179
Study 3042041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine (group II)
Number of subjects: 179
Study 3042041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone alone (group III)
Number of subjects: 179
Study 30569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Attention Training (SAT)
Number of subjects: 0
Study 30569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT)
Number of subjects: 0
Study 30569816 — intervention group
Group type: COMPARATOR
Intervention: Selective Attention Training (SAT) and Working Memory Training (WMT)
Number of subjects: 0
Study 29953876 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g inulin (0.5 g U-13C-inulin)
Number of subjects: 14
Study 29953876 — intervention group
Group type: COMPARATOR
Intervention: 24 g maltodextrin placebo
Number of subjects: 14
Study 26639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 120
Study 26639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Number of subjects: 120
Study 26639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Number of subjects: 120
Study 26639952 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 120
Study 25764376 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic NOSE colectomy
Number of subjects: 40
Study 25764376 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic colectomy
Number of subjects: 40
Study 23329236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/docetaxel (cisplatin 75 mg/m² and docetaxel 75 mg/m² every 3 weeks)
Number of subjects: 88
Study 23329236 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin/docetaxel (oxaliplatin 85 mg/m² and docetaxel 50 mg/m² every 2 weeks)
Number of subjects: 88
Study 23329236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/docetaxel
Number of subjects: 88
Study 23329236 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin/docetaxel
Number of subjects: 88
Study 21589675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar prosthesis (cemented or cementless)
Number of subjects: 50